Biological Variability of Soluble ST2 in Patients with Stable Chronic Heart Failure and Implications for Monitoring

TY - JOUR

T1 - Biological Variability of Soluble ST2 in Patients with Stable Chronic Heart Failure and Implications for Monitoring

AU - Piper, Susan

AU - deCourcey, Julia

AU - Sherwood, Roy

AU - Amin-Youssef, George

AU - McDonagh, Theresa

PY - 2016/4/21

Y1 - 2016/4/21

N2 - Soluble ST2 (sST2) is a novel biomarker implicated in myocardial remodelling and fibrosis. Recent studies in normal subjects have suggested the biological variability (BV) of sST2 is significantly lower than that of the B-type natriuretic peptides, BNP & NTproBNP. It may, consequently, be a better biomarker for monitoring patients with chronic heart failure (CHF). To date, no published studies have examined the BV of sST2 in a heart failure population. Blood samples from 50 outpatients with pharmacologically optimised stable CHF and persistent left ventricular dysfunction (ejection fraction (EF) <40%). were collected at baseline, 1 hour, 1 month, 3 months and 6 months. Using log-transformed data, mean intra-individual coefficients of variation (CVI) and subsequent reference change values (RCV) were calculated for both NTproBNP and sST2. Results demonstrate significantly lower CVI and RCV for sST2 compared with NTproBNP at 1 month (12.02 (36%) vs. 36.75 (103%)) p<0.001, 3 months (12.23 (36%) vs. 40.98 (114%)) p<0.001 and 6 months (16.41 (47%) vs. 46.02 (128%)) p<0.001. In conclusion, the BV of sST2 is significantly lower than that of NTproBNP in patients with CHF. These results support previous indications that sST2 may be a better biomarker for monitoring such patients.

AB - Soluble ST2 (sST2) is a novel biomarker implicated in myocardial remodelling and fibrosis. Recent studies in normal subjects have suggested the biological variability (BV) of sST2 is significantly lower than that of the B-type natriuretic peptides, BNP & NTproBNP. It may, consequently, be a better biomarker for monitoring patients with chronic heart failure (CHF). To date, no published studies have examined the BV of sST2 in a heart failure population. Blood samples from 50 outpatients with pharmacologically optimised stable CHF and persistent left ventricular dysfunction (ejection fraction (EF) <40%). were collected at baseline, 1 hour, 1 month, 3 months and 6 months. Using log-transformed data, mean intra-individual coefficients of variation (CVI) and subsequent reference change values (RCV) were calculated for both NTproBNP and sST2. Results demonstrate significantly lower CVI and RCV for sST2 compared with NTproBNP at 1 month (12.02 (36%) vs. 36.75 (103%)) p<0.001, 3 months (12.23 (36%) vs. 40.98 (114%)) p<0.001 and 6 months (16.41 (47%) vs. 46.02 (128%)) p<0.001. In conclusion, the BV of sST2 is significantly lower than that of NTproBNP in patients with CHF. These results support previous indications that sST2 may be a better biomarker for monitoring such patients.

KW - Heart Failure

KW - Monitoring

KW - Biomarkers

U2 - 10.1016/j.amjcard.2016.04.017

DO - 10.1016/j.amjcard.2016.04.017

M3 - Article

SN - 0002-9149

JO - American Journal of Cardiology

JF - American Journal of Cardiology

ER -